ClinicalTrials.gg
CompletedNCT00091832Updated Jan 28, 2014Results posted

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

A Phase 2 interventional study of Denosumab and IV Bisphosphonates in Breast Cancer, Metastases and Bone Metastases in Subjects With Advanced Breast Cancer, sponsored by Amgen. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-28.

Sponsored by Amgen · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.

Enrollment
7th of 24
255 · median 53
Started
2004
with 1 other
Phase 2
9 of 24
none open now
Registered
2nd of 24
by date
Lead sponsor
8 of 24
Amgen

Among the 24 studies testing denosumab in Breast Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2004, is one of 9 in phase 2, and was the 2nd registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing denosumab in Breast Neoplasms as a file.
02

Study summary

This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.

03

Conditions studied

  • Breast Cancer
  • Metastases
  • Bone Metastases in Subjects With Advanced Breast Cancer

Keywords

  • Breast Cancer
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - or cytologically confirmed breast adenocarcinoma

  • At least one bone
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Denosumab 60 mg every 12 weeks

    Denosumab 60 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.

    Biological: Denosumab

  • Experimental
    Denosumab 120 mg every 4 weeks

    Denosumab 120 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.

    Biological: Denosumab

  • Experimental
    Denosumab 180 mg every 4 weeks

    Denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.

    Biological: Denosumab

  • Active comparator
    IV bisphosphonates every 4 weeks

    Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion for 25 weeks.

    Drug: IV Bisphosphonates

  • Experimental
    Denosumab 180 mg every 12 weeks

    Denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.

    Biological: Denosumab

  • Experimental
    Denosumab 30 mg every 4 weeks

    Denosumab 30 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.

    Biological: Denosumab

Interventions

  • BiologicalDenosumab

    Denosumab administered by subcutaneous injection

    Also known as: AMG 162

  • Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)

    Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and Week 13

Secondary outcomes

  1. Percent Change From Baseline to Week 25 in Urinary N-telopeptide (uNTx)

    Percent change from Baseline to Week 25 in Urinary N-telopeptide (uNTx) calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.

    Time frame: Baseline and Week 25

  2. Number of Participants Achieving 65% or More Reduction in Urinary N-telopeptide (uNTx) From Baseline at Week 13

    The number of participants achieving a 65% reduction or more in uNTx from Baseline at Week 13. Calculation used is ((Week 13 value - Baseline value) / Baseline value ) x 100 and participants were considered having a 65% reduction or more if their value was ≤ -65%.

    Time frame: Baseline and Week 13

  3. Number of Participants Achieving 65% or More Reduction in uNTX From Baseline at Week 25

    The number of participants achieving a 65% reduction or more in uNTX from Baseline at Week 25. Calculation used is ((Week 25 value - Baseline value) / Baseline value) x 100 and participants were considered having a 65% reduction or more if their value was ≤ -65%.

    Time frame: Baseline and Week 25

  4. Time to 65% or More Reduction in Urinary N-telopeptide (uNTX) From Baseline

    Kaplan-Meier estimate of the median time from enrollment to the first occurrence of a reduction of uNTx of ≥ 65% compared to Baseline. For participants whose uNTx did not fall below 65% of the Baseline value, the time was censored at time of last evaluation of uNTx.

    Time frame: Baseline to Week 57

  5. Percent Change From Baseline to Week 13 in Serum C-Telopeptide (CTX)

    Percent change from Baseline to Week 13 in type I serum C-telopeptide (CTX) calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.

    Time frame: Baseline and week 13

  6. Percent Change From Baseline to Week 25 in Serum C-telopeptide (CTX)

    Percent change from Baseline to Week 25 in type I serum C-telopeptide calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.

    Time frame: Baseline and Week 25

  7. Percent Change From Baseline to Week 13 in Procollagen I N-terminal Peptide (P1NP)

    Percent change from Baseline to Week 13 in procollagen 1 N-terminal peptide calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.

    Time frame: Baseline and Week 13

  8. Percent Change From Baseline to Week 25 in P1NP

    Percent change from Baseline to Week 25 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Week 25 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and Week 25

  9. Percent Change From Baseline to Week 13 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)

    Percent change from Baseline to Week 13 in tartrate-resistant acid phosphatase 5b calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.

    Time frame: Baseline and Week 13

  10. Percent Change From Baseline to Week 25 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)

    Percent change from Baseline to Week 25 in TRAP5b calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.

    Time frame: Baseline and Week 25

  11. Percent Change From Baseline to Week 13 in Bone Specific Alkaline Phosphatase (BSAP)

    Percent change from Baseline to Week 13 in bone specific alkaline phosphatase (BSAP) calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.

    Time frame: Baseline and Week 13

  12. Percent Change From Baseline to Week 25 in Bone Specific Alkaline Phosphatase (BSAP)

    Percent change from Baseline to Week 25 in BSAP calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.

    Time frame: Baseline and Week 25

  13. Percent Change From Baseline to Week 13 in Osteocalcin

    Percent change from Baseline to Week 13 in osteocalcin calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and Week 13

  14. Percent Change From Baseline to Week 25 in Osteocalcin

    Percent change from Baseline to Week 25 in osteocalcin calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.

    Time frame: Baseline and Week 25

  15. Time to First Skeletal Related Event

    Skeletal Related Event (SRE) defined as ≥ 1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes).

    Time frame: Day 1 to Week 25

  16. Number of Participants With Skeletal Related Events

    Skeletal Related Events (SRE) are defined as ≥ 1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes).

    Time frame: From Day 1 to Week 25

  17. Number of Participants With Hypercalcemia

    Occurrence of grade 3 or 4 hypercalcemia according to the Common Terminology Criteria for Adverse Events (CTCAE) v3. A summary of hypercalcemia events is reported under adverse events.

    Time frame: Day 1 to Week 57

07

Results

Posted Jan 7, 2011

Participant flow

Participants were enrolled from 8 September 2004 through 9 May 2005

Participant flow — Overall Study
MilestoneBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Started434242434243
Received study medication434241434243
Completed293130292732
Not completed141112141511
Withdrew: Physician decision100000
Withdrew: Adverse event000130
Withdrew: Withdrawal by subject450131
Withdrew: Death645856
Withdrew: Disease progression200112
Withdrew: Ineligibility determined001010
Withdrew: Lost to follow-up103321
Withdrew: Noncompliance010000
Withdrew: Other012000
Withdrew: Protocol violation001001

Outcome measures

PrimaryPercent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)

Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and Week 13
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)-10.19 ± 208.84-52.87 ± 95.14-54.21 ± 61.34-57.36 ± 41.46-51.73 ± 60.85-18.46 ± 125.86
Statistical analysis
  • Bisphosphonate IV Q4W vs Denosumab 30 mg Q4W vs Denosumab 120 mg Q4W vs Denosumab 180 mg Q4W vs Denosumab 60 mg Q12W vs Denosumab 180 mg Q12W · ANCOVA · p = 0.245Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
SecondaryPercent Change From Baseline to Week 25 in Urinary N-telopeptide (uNTx)

Percent change from Baseline to Week 25 in Urinary N-telopeptide (uNTx) calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.

Time frame:
Baseline and Week 25
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 25 in Urinary N-telopeptide (uNTx)
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 25 in Urinary N-telopeptide (uNTx)-39.52 ± 74.16-53.46 ± 100.77-43.16 ± 101.08-59.41 ± 43.31-41.79 ± 72.61-39.96 ± 65.85
Statistical analysis
  • Bisphosphonate IV Q4W vs Denosumab 30 mg Q4W vs Denosumab 120 mg Q4W vs Denosumab 180 mg Q4W vs Denosumab 60 mg Q12W vs Denosumab 180 mg Q12W · ANCOVA · p = 0.848Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
SecondaryNumber of Participants Achieving 65% or More Reduction in Urinary N-telopeptide (uNTx) From Baseline at Week 13

The number of participants achieving a 65% reduction or more in uNTx from Baseline at Week 13. Calculation used is ((Week 13 value - Baseline value) / Baseline value ) x 100 and participants were considered having a 65% reduction or more if their value was ≤ -65%.

Time frame:
Baseline and Week 13
Reported as:
Number · Participants
Number of Participants Achieving 65% or More Reduction in Urinary N-telopeptide (uNTx) From Baseline at Week 13
ParticipantsBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Number of Participants Achieving 65% or More Reduction in Urinary N-telopeptide (uNTx) From Baseline at Week 13252426242021
Statistical analysis
  • Bisphosphonate IV Q4W vs Denosumab 60 mg Q12W · Odds ratio (or): 1.72 · 95% CI 0.68 to 4.35Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 180 mg Q4W · Odds ratio (or): 1.29 · 95% CI 0.51 to 3.24Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 120 mg Q4W · Odds ratio (or): 0.88 · 95% CI 0.34 to 2.29Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 30 mg Q4W · Odds ratio (or): 1.27 · 95% CI 0.51 to 3.20Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 180 mg Q12W · Odds ratio (or): 1.74 · 95% CI 0.70 to 4.34Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
SecondaryNumber of Participants Achieving 65% or More Reduction in uNTX From Baseline at Week 25

The number of participants achieving a 65% reduction or more in uNTX from Baseline at Week 25. Calculation used is ((Week 25 value - Baseline value) / Baseline value) x 100 and participants were considered having a 65% reduction or more if their value was ≤ -65%.

Time frame:
Baseline and Week 25
Reported as:
Number · Participants
Number of Participants Achieving 65% or More Reduction in uNTX From Baseline at Week 25
ParticipantsBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Number of Participants Achieving 65% or More Reduction in uNTX From Baseline at Week 25192523252115
Statistical analysis
  • Bisphosphonate IV Q4W vs Denosumab 180 mg Q12W · Odds ratio (or): 1.82 · 95% CI 0.69 to 4.79Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 180 mg Q4W · Odds ratio (or): 0.67 · 95% CI 0.25 to 1.76Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 120 mg Q4W · Odds ratio (or): 0.65 · 95% CI 0.24 to 1.77Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 30 mg Q4W · Odds ratio (or): 0.58 · 95% CI 0.22 to 1.58Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 60 mg Q12W · Odds ratio (or): 0.70 · 95% CI 0.25 to 1.92Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
SecondaryTime to 65% or More Reduction in Urinary N-telopeptide (uNTX) From Baseline

Kaplan-Meier estimate of the median time from enrollment to the first occurrence of a reduction of uNTx of ≥ 65% compared to Baseline. For participants whose uNTx did not fall below 65% of the Baseline value, the time was censored at time of last evaluation of uNTx.

Time frame:
Baseline to Week 57
Reported as:
Median · Days
Time to 65% or More Reduction in Urinary N-telopeptide (uNTX) From Baseline
DaysBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Time to 65% or More Reduction in Urinary N-telopeptide (uNTX) From Baseline10 (8 to 86)13 (8 to 57)11 (9 to 43)10 (8 to 42)9 (8 to 29)30 (9 to 141)
Statistical analysis
  • Bisphosphonate IV Q4W vs Denosumab 180 mg Q12W · Hazard ratio (hr): 0.82 · 95% CI 0.51 to 1.31A hazard ratio \>1 indicates that the time to 65% or more reduction in uNTx from baseline was shorter in the Denosumab-treated group than in the control group.
  • Bisphosphonate IV Q4W vs Denosumab 180 mg Q4W · Hazard ratio (hr): 1.03 · 95% CI 0.64 to 1.65A hazard ratio \>1 indicates that the time to 65% or more reduction in uNTx from baseline was shorter in the Denosumab-treated group than in the control group.
  • Bisphosphonate IV Q4W vs Denosumab 120 mg Q4W · Hazard ratio (hr): 1.09 · 95% CI 0.68 to 1.74A hazard ratio \>1 indicates that the time to 65% or more reduction in uNTx from baseline was shorter in the Denosumab-treated group than in the control group.
  • Bisphosphonate IV Q4W vs Denosumab 30 mg Q4W · Hazard ratio (hr): 1.09 · 95% CI 0.68 to 1.74A hazard ratio \>1 indicates that the time to 65% or more reduction in uNTx from baseline was shorter in the Denosumab-treated group than in the control group.
  • Bisphosphonate IV Q4W vs Denosumab 60 mg Q12W · Hazard ratio (hr): 1.14 · 95% CI 0.71 to 1.83A hazard ratio \>1 indicates that the time to 65% or more reduction in uNTx from baseline was shorter in the Denosumab-treated group than in the control group.
SecondaryPercent Change From Baseline to Week 13 in Serum C-Telopeptide (CTX)

Percent change from Baseline to Week 13 in type I serum C-telopeptide (CTX) calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.

Time frame:
Baseline and week 13
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 13 in Serum C-Telopeptide (CTX)
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 13 in Serum C-Telopeptide (CTX)-66.92 ± 44.05-80.76 ± 12.66-78.45 ± 28.89-81.79 ± 13.29-70.50 ± 41.76-78.13 ± 16.66
SecondaryPercent Change From Baseline to Week 25 in Serum C-telopeptide (CTX)

Percent change from Baseline to Week 25 in type I serum C-telopeptide calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.

Time frame:
Baseline and Week 25
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 25 in Serum C-telopeptide (CTX)
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 25 in Serum C-telopeptide (CTX)-73.09 ± 22.42-82.70 ± 11.92-74.48 ± 30.26-80.07 ± 22.26-70.64 ± 36.94-78.31 ± 14.00
SecondaryPercent Change From Baseline to Week 13 in Procollagen I N-terminal Peptide (P1NP)

Percent change from Baseline to Week 13 in procollagen 1 N-terminal peptide calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.

Time frame:
Baseline and Week 13
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 13 in Procollagen I N-terminal Peptide (P1NP)
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 13 in Procollagen I N-terminal Peptide (P1NP)-50.75 ± 29.47-52.35 ± 36.90-48.23 ± 36.83-50.47 ± 54.67-43.94 ± 44.53-59.42 ± 18.60
SecondaryPercent Change From Baseline to Week 25 in P1NP

Percent change from Baseline to Week 25 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Week 25 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and Week 25
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 25 in P1NP
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 25 in P1NP-50.48 ± 41.22-53.48 ± 54.79-55.90 ± 30.66-57.88 ± 51.97-51.18 ± 40.41-51.37 ± 47.53
SecondaryPercent Change From Baseline to Week 13 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)

Percent change from Baseline to Week 13 in tartrate-resistant acid phosphatase 5b calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.

Time frame:
Baseline and Week 13
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 13 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 13 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)-37.45 ± 19.87-56.07 ± 17.80-58.24 ± 15.07-53.12 ± 50.00-55.85 ± 27.22-55.91 ± 17.61
SecondaryPercent Change From Baseline to Week 25 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)

Percent change from Baseline to Week 25 in TRAP5b calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.

Time frame:
Baseline and Week 25
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 25 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 25 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)-38.59 ± 26.06-58.58 ± 18.93-52.39 ± 25.30-51.15 ± 44.49-56.25 ± 32.30-53.13 ± 22.23
SecondaryPercent Change From Baseline to Week 13 in Bone Specific Alkaline Phosphatase (BSAP)

Percent change from Baseline to Week 13 in bone specific alkaline phosphatase (BSAP) calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.

Time frame:
Baseline and Week 13
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 13 in Bone Specific Alkaline Phosphatase (BSAP)
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 13 in Bone Specific Alkaline Phosphatase (BSAP)-40.01 ± 24.4226.37 ± 406.79-40.23 ± 27.34-38.42 ± 25.44-37.11 ± 31.33-35.94 ± 25.49
SecondaryPercent Change From Baseline to Week 25 in Bone Specific Alkaline Phosphatase (BSAP)

Percent change from Baseline to Week 25 in BSAP calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.

Time frame:
Baseline and Week 25
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 25 in Bone Specific Alkaline Phosphatase (BSAP)
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 25 in Bone Specific Alkaline Phosphatase (BSAP)-46.56 ± 26.0215.88 ± 347.47-49.01 ± 21.24-52.60 ± 16.23-46.72 ± 23.25-48.24 ± 27.61
SecondaryPercent Change From Baseline to Week 13 in Osteocalcin

Percent change from Baseline to Week 13 in osteocalcin calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and Week 13
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 13 in Osteocalcin
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 13 in Osteocalcin6.82 ± 49.78-19.35 ± 38.71-2.39 ± 47.96-6.23 ± 40.82-23.78 ± 35.46-5.96 ± 41.92
SecondaryPercent Change From Baseline to Week 25 in Osteocalcin

Percent change from Baseline to Week 25 in osteocalcin calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.

Time frame:
Baseline and Week 25
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 25 in Osteocalcin
Percent changeBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Percent Change From Baseline to Week 25 in Osteocalcin-4.74 ± 86.98-30.78 ± 34.94-22.80 ± 46.36-26.95 ± 41.49-23.93 ± 43.99-22.69 ± 36.79
SecondaryTime to First Skeletal Related Event

Skeletal Related Event (SRE) defined as ≥ 1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes).

Time frame:
Day 1 to Week 25
Reported as:
Median · Days
Time to First Skeletal Related Event
DaysBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Time to First Skeletal Related EventNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Bisphosphonate IV Q4W vs Denosumab 30 mg Q4W · Hazard ratio (hr): 0.543 · 95% CI 0.159 to 1.856A hazard ratio \<1 indicates the time to the first skeletal-related event in the denosumab-treated group was longer than that in the control group.
  • Bisphosphonate IV Q4W vs Denosumab 60 mg Q12W · Hazard ratio (hr): 0.544 · 95% CI 0.159 to 1.859A hazard ratio \<1 indicates the time to the first skeletal-related event in the denosumab-treated group was longer than that in the control group.
  • Bisphosphonate IV Q4W vs Denosumab 180 mg Q4W · Hazard ratio (hr): 0.791 · 95% CI 0.266 to 2.355A hazard ratio \<1 indicates the time to the first skeletal-related event in the denosumab-treated group was longer than that in the control group.
  • Bisphosphonate IV Q4W vs Denosumab 120 mg Q4W · Hazard ratio (hr): 1.073 · 95% CI 0.389 to 2.963A hazard ratio \<1 indicates the time to the first skeletal-related event in the denosumab-treated group was longer than that in the control group.
  • Bisphosphonate IV Q4W vs Denosumab 180 mg Q12W · Hazard ratio (hr): 0.540 · 95% CI 0.158 to 1.847A hazard ratio \<1 indicates the time to the first skeletal-related event in the denosumab-treated group was longer than that in the control group.
SecondaryNumber of Participants With Skeletal Related Events

Skeletal Related Events (SRE) are defined as ≥ 1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes).

Time frame:
From Day 1 to Week 25
Reported as:
Number · Participants
Number of Participants With Skeletal Related Events
ParticipantsBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Number of Participants With Skeletal Related Events748644
Statistical analysis
  • Bisphosphonate IV Q4W vs Denosumab 180 mg Q12W · Odds ratio (or): 1.92 · 95% CI 0.51 to 7.17Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 180 mg Q4W · Odds ratio (or): 1.20 · 95% CI 0.36 to 3.97Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 120 mg Q4W · Odds ratio (or): 0.81 · 95% CI 0.26 to 2.52Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 60 mg Q12W · Odds ratio (or): 1.88 · 95% CI 0.5 to 7.05Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
  • Bisphosphonate IV Q4W vs Denosumab 30 mg Q4W · Odds ratio (or): 1.88 · 95% CI 0.5 to 7.05Adjusted for the stratum to which the participant was originally assigned by the Interactive Voice Response System (IVRS)
SecondaryNumber of Participants With Hypercalcemia

Occurrence of grade 3 or 4 hypercalcemia according to the Common Terminology Criteria for Adverse Events (CTCAE) v3. A summary of hypercalcemia events is reported under adverse events.

Time frame:
Day 1 to Week 57
Reported as:
Number · Participants
Number of Participants With Hypercalcemia
ParticipantsBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Number of Participants With Hypercalcemia000000

Adverse events

Collected over 25 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bisphosphonate IV Q4W—15/43 (34.9%)36/43 (83.7%)
Denosumab 30 mg Q4W—11/42 (26.2%)33/42 (78.6%)
Denosumab 120 mg Q4W—19/41 (46.3%)37/41 (90.2%)
Denosumab 180 mg Q4W—16/43 (37.2%)36/43 (83.7%)
Denosumab 60 mg Q12W—14/42 (33.3%)37/42 (88.1%)
Denosumab 180 mg Q12W—15/43 (34.9%)35/43 (81.4%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
Pleural effusionRespiratory, thoracic and mediastinal disorders2/430/423/410/434/420/43
General physical health deteriorationGeneral disorders0/430/421/414/430/421/43
AnaemiaBlood and lymphatic system disorders0/431/423/410/432/421/43
Febrile neutropeniaBlood and lymphatic system disorders1/430/422/410/433/420/43
VomitingGastrointestinal disorders0/430/422/411/430/421/43
PyrexiaGeneral disorders1/430/422/411/430/421/43
DyspnoeaRespiratory, thoracic and mediastinal disorders1/430/422/411/430/420/43
NauseaGastrointestinal disorders0/430/421/410/430/422/43
Urinary tract infectionInfections and infestations2/430/420/410/430/420/43
CachexiaMetabolism and nutrition disorders0/431/421/412/431/420/43
Most frequent other events
Showing 10 of 48
Most frequent other events
EventBisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 120 mg Q4WDenosumab 180 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12W
AstheniaGeneral disorders12/439/429/414/436/425/43
ArthralgiaMusculoskeletal and connective tissue disorders12/433/424/419/435/423/43
VomitingGastrointestinal disorders8/4311/427/415/437/424/43
NauseaGastrointestinal disorders10/4310/429/4111/437/429/43
DiarrhoeaGastrointestinal disorders7/439/429/416/434/426/43
Back painMusculoskeletal and connective tissue disorders4/437/429/415/434/425/43
MyalgiaMusculoskeletal and connective tissue disorders9/433/421/411/431/422/43
HeadacheNervous system disorders7/434/426/416/438/424/43
PyrexiaGeneral disorders8/432/424/413/433/423/43
Bone painMusculoskeletal and connective tissue disorders8/432/427/416/435/424/43

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Bisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12WDenosumab 120 mg Q4WDenosumab 180 mg Q4WTotal
Mean52.0 ± 10.756.5 ± 10.859.2 ± 12.358.2 ± 9.157.4 ± 11.057.6 ± 13.957.8 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Bisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12WDenosumab 120 mg Q4WDenosumab 180 mg Q4WTotal
Female434242434243255
Male0000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12WDenosumab 120 mg Q4WDenosumab 180 mg Q4WTotal
White or Caucasian252829343033179
Hispanic or Latino1613139101071
Asian1000102
Native Hawaiian or Other Pacific Islander0100001
Other1000102
uNTx/Cr
uNTx/Cr(nmol/mmol)Bisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12WDenosumab 120 mg Q4WDenosumab 180 mg Q4WTotal
Mean83.16 ± 94.3766.44 ± 61.1789.41 ± 98.5875.92 ± 91.03102.06 ± 129.1298.22 ± 168.4285.78 ± 111.94
Serum CTx
Serum CTx(ng/mL)Bisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12WDenosumab 120 mg Q4WDenosumab 180 mg Q4WTotal
Mean0.592 ± 0.2840.632 ± 0.4300.720 ± 0.5590.647 ± 0.7030.714 ± 0.5640.846 ± 0.8920.692 ± 0.605
TRAP 5b
TRAP 5b(U/L)Bisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12WDenosumab 120 mg Q4WDenosumab 180 mg Q4WTotal
Mean6.907 ± 3.2806.879 ± 2.8787.116 ± 3.4937.628 ± 6.8306.765 ± 4.3407.009 ± 4.2177.057 ± 4.358
BSAP
BSAP(U/L)Bisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12WDenosumab 120 mg Q4WDenosumab 180 mg Q4WTotal
Mean54.84 ± 51.6944.33 ± 26.0645.62 ± 26.0262.39 ± 109.1847.89 ± 30.4648.82 ± 35.1350.75 ± 55.04
P1NP
P1NP(µg/L)Bisphosphonate IV Q4WDenosumab 30 mg Q4WDenosumab 60 mg Q12WDenosumab 180 mg Q12WDenosumab 120 mg Q4WDenosumab 180 mg Q4WTotal
Mean111.01 ± 97.2198.54 ± 72.69114.29 ± 113.51193.03 ± 641.1398.47 ± 83.46139.01 ± 188.02126.20 ± 284.81

1 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Campbell-Baird C, Lipton A, Sarkenshik M, Ma H, Jun S.Incidence of Acute Phase Events Following Denosumab or Intravenous Bisphosphonates: Results From a Randomized, Controlled Phase 2 Study in Patients With Breast Cancer and Bone Metastases.Journal-001752;2010;7:85-89.
  • Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, Jun S. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res. 2008 Oct 15;14(20):6690-6. doi: 10.1158/1078-0432.CCR-07-5234. PubMed 18927312 ↗
  • Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007 Oct 1;25(28):4431-7. doi: 10.1200/JCO.2007.11.8604. Epub 2007 Sep 4. PubMed 17785705 ↗
  • Peterson M, Rodriquez R., Gurrola E., Sohn W, Jun S (others??).Population pharmacokinetics and pharmacodynamics of denosumab in breast cancer patients with bone metastases.Journal-000709;
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Nov 2005 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 5 years 2 months after primary completion. A results delay was requested in Nov 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2004
First posted
Sep 21, 2004
Start
Sep 2004
Primary completionActual
Nov 2005
CompletionActual
Oct 2006
Results delay requested
Nov 23, 2009
Results first posted
Jan 7, 2011
Last update
Jan 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00091832
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 21, 2004
Start date
Sep 2004
Primary completion
Nov 2005
Completion
Oct 2006
Results posted
Jan 7, 2011
Last update
Jan 28, 2014

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion